| Document And Entity Information | 6 Months Ended |
| Sep. 30, 2023 | |
| Document Information Line Items | |
| Entity Registrant Name | CHINA JO-JO DRUGSTORES, INC. |
| Document Type | 6-K |
| Current Fiscal Year End Date | --03-31 |
| Amendment Flag | false |
| Entity Central Index Key | 0001856084 |
| Document Period End Date | Sep. 30, 2023 |
| Document Fiscal Year Focus | 2024 |
| Document Fiscal Period Focus | Q2 |
| Entity File Number | 001-40724 |
| Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2023 | Mar. 31, 2023 |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $ 18,649,931 | $ 18,807,936 |
| Restricted cash | 10,950,389 | 12,762,708 |
| Trade receivable | 17,512,742 | 14,119,606 |
| Inventories | 19,591,140 | 15,309,100 |
| Other receivables, net | 2,152,125 | 2,725,015 |
| Advances to suppliers | 444,323 | 142,417 |
| Other current assets | 520,537 | 616,008 |
| Total current assets | 69,821,187 | 64,482,790 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net | 4,672,145 | 5,100,264 |
| Long-term investment | 1,159,275 | 1,772,072 |
| Farmland assets | 627,573 | 666,721 |
| Long-term deposits | 1,087,694 | 1,038,125 |
| Other noncurrent assets | 725,111 | 790,056 |
| Operating lease right-of-use assets | 13,683,765 | 13,924,826 |
| Intangible assets, net | 2,990,780 | 3,195,748 |
| Total non-current assets | 24,946,343 | 26,487,812 |
| Total assets | 94,767,530 | 90,970,602 |
| CURRENT LIABILITIES | ||
| Accounts payable | 34,401,260 | 26,990,250 |
| Notes payable | 24,522,897 | 29,255,776 |
| Other payables | 1,677,055 | 1,314,919 |
| Other payables - related parties | 1,450,423 | 683,560 |
| Customer deposits | 654,664 | 695,931 |
| Taxes payable | 1,656,743 | 1,706,909 |
| Accrued liabilities | 378,222 | 756,516 |
| Current portion of operating lease liabilities | 5,043,017 | 5,131,373 |
| Total current liabilities | 69,784,281 | 66,535,234 |
| Long-term operating lease liabilities | 7,445,300 | 7,768,216 |
| Total liabilities | 77,229,581 | 74,303,450 |
| COMMITMENTS AND CONTINGENCIES | ||
| SHAREHOLDERS’ EQUITY | ||
| Ordinary shares; $0.24 par value; 150,000,000 shares authorized; 1,682,861 and 1,184,861 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively | 403,887 | 284,367 |
| Preferred shares; $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of September 30, 2023 and March 31, 2023 | ||
| Additional paid-in capital | 86,428,498 | 83,958,418 |
| Statutory reserves | 1,309,109 | 1,309,109 |
| Accumulated deficit | (70,197,265) | (69,273,018) |
| Accumulated other comprehensive income | 940,593 | 1,735,135 |
| Total shareholders’ equity attributed to China Jo-Jo | 18,884,822 | 18,014,011 |
| Noncontrolling interests | (1,346,873) | (1,346,859) |
| Total shareholders’ equity | 17,537,949 | 16,667,152 |
| Total liabilities and shareholders’ equity | $ 94,767,530 | $ 90,970,602 |
| Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2023 | Mar. 31, 2023 |
| Statement of Financial Position [Abstract] | ||
| Ordinary shares, par value (in Dollars per share) | $ 0.24 | $ 0.24 |
| Ordinary shares, shares authorized | 150,000,000 | 150,000,000 |
| Ordinary shares, shares issued | 1,682,861 | 1,184,861 |
| Ordinary shares, shares outstanding | 1,682,861 | 1,184,861 |
| Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 |
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
| Preferred stock, shares issued | ||
| Preferred stock, shares outstanding |
| Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 6 Months Ended | |
| Sep. 30, 2023 | Sep. 30, 2022 | |
| Income Statement [Abstract] | ||
| REVENUES, NET | $ 78,574,409 | $ 72,722,085 |
| COST OF GOODS SOLD | 62,641,320 | 55,801,399 |
| GROSS PROFIT | 15,933,089 | 16,920,686 |
| SELLING EXPENSES | 14,044,750 | 14,530,119 |
| GENERAL AND ADMINISTRATIVE EXPENSES | 1,632,357 | 3,635,251 |
| TOTAL OPERATING EXPENSES | 15,677,107 | 18,165,370 |
| INCOME (LOSS) FROM OPERATIONS | 255,982 | (1,244,684) |
| OTHER INCOME (EXPENSES): | ||
| INTEREST INCOME | 216,891 | 145,107 |
| INTEREST EXPENSE | (307) | (60,365) |
| INVESTMENT LOSS | (1,642,910) | |
| OTHER INCOME | 285,255 | 1,003,696 |
| TOTAL OTHER INCOME (EXPENSES) | (1,141,071) | 1,088,438 |
| LOSS BEFORE INCOME TAXES | (885,089) | (156,246) |
| PROVISION FOR INCOME TAXES | 39,172 | 438,788 |
| NET LOSS | (924,261) | (595,034) |
| LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | (14) | (253) |
| NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC. | (924,247) | (594,781) |
| OTHER COMPREHENSIVE LOSS | ||
| FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | (794,542) | (3,428,158) |
| COMPREHENSIVE LOSS | $ (1,718,803) | $ (4,023,192) |
| WEIGHTED AVERAGE NUMBER OF SHARES: | ||
| Basic (in Shares) | 1,195,746 | 226,702 |
| Diluted (in Shares) | 1,195,746 | 226,702 |
| LOSS PER SHARE: | ||
| Basic (in Dollars per share) | $ (0.77) | $ (2.62) |
| Diluted (in Dollars per share) | $ (0.77) | $ (2.62) |
| Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($) | Common Stock | Additional paid-in capital | Retained Earnings Statutory reserves | Retained Earnings Accumulated deficit | Accumulated other comprehensive income/(loss) | Non- controlling interest | Total |
| Balance at Mar. 31, 2022 | $ 41,752 | $ 66,516,033 | $ 1,309,109 | $ (48,134,493) | $ 4,352,992 | $ (1,346,607) | $ 22,738,786 |
| Balance (in Shares) at Mar. 31, 2022 | 173,966 | ||||||
| Issuance of incentive ordinary shares award | $ 10,200 | 1,706,800 | 1,717,000 | ||||
| Issuance of incentive ordinary shares award (in Shares) | 42,500 | ||||||
| Sale of shares and warrants | $ 12,000 | 1,488,000 | 1,500,000 | ||||
| Sale of shares and warrants (in Shares) | 50,000 | ||||||
| Fractional shares issued for reverse stock split | $ 97 | (97) | |||||
| Fractional shares issued for reverse stock split (in Shares) | 402 | ||||||
| Net loss | (594,781) | (253) | (595,034) | ||||
| Foreign currency translation loss | (3,428,158) | (3,428,158) | |||||
| Balance at Sep. 30, 2022 | $ 64,049 | 69,710,736 | 1,309,109 | (48,729,274) | 924,834 | (1,346,860) | 21,932,594 |
| Balance (in Shares) at Sep. 30, 2022 | 266,868 | ||||||
| Balance at Mar. 31, 2023 | $ 284,367 | 83,958,418 | 1,309,109 | (69,273,018) | 1,735,135 | (1,346,859) | $ 16,667,152 |
| Balance (in Shares) at Mar. 31, 2023 | 1,184,861 | 1,184,861 | |||||
| Sale of shares and warrants | $ 119,520 | 2,470,080 | $ 2,589,600 | ||||
| Sale of shares and warrants (in Shares) | 498,000 | ||||||
| Net loss | (924,247) | (14) | (924,261) | ||||
| Foreign currency translation loss | (794,542) | (794,542) | |||||
| Balance at Sep. 30, 2023 | $ 403,887 | $ 86,428,498 | $ 1,309,109 | $ (70,197,265) | $ 940,593 | $ (1,346,873) | $ 17,537,949 |
| Balance (in Shares) at Sep. 30, 2023 | 1,682,861 | 1,682,861 |
| Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
| Sep. 30, 2023 | Sep. 30, 2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $ (924,261) | $ (595,034) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Bad debt direct write-off and provision | (888,847) | (753,494) |
| Depreciation and amortization | 320,966 | 630,533 |
| Investment loss | 1,642,910 | |
| Stock based compensation | 1,717,000 | |
| Accounts receivable | (3,341,534) | (1,662,260) |
| Notes receivable | 20,051 | (236,163) |
| Inventories and biological assets | (5,302,535) | (3,090,129) |
| Other receivables | 283,624 | (1,408,534) |
| Advances to suppliers | (317,550) | 35,530 |
| Other current assets | (174,537) | (230,581) |
| Long term deposit | (113,118) | 60,394 |
| Other noncurrent assets | 18,991 | (22,334) |
| Accounts payable | 9,206,918 | 5,179,339 |
| Other payables and accrued liabilities | 240,804 | 861,324 |
| Customer deposits | (413) | (318,899) |
| Taxes payable | 51,233 | 891,050 |
| Net cash provided by operating activities | 722,702 | 1,057,742 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Acquisition of equipment | (9,294) | (25,633) |
| Purchases of intangible assets | (27,335) | |
| Investment in a joint venture | (1,122,224) | |
| Additions to leasehold improvements | (166,765) | (57,788) |
| Net cash (used in) investing activities | (1,325,618) | (83,421) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Repayment of third parties loan | (1,278,211) | |
| Proceeds from notes payable | 25,098,414 | 29,169,681 |
| Repayment of notes payable | (28,184,237) | (32,216,676) |
| Proceeds from sale of shares and warrants | 2,589,600 | 1,500,000 |
| Repayment of other payables-related parties | 824,146 | (158,409) |
| Net cash provided by (used in) financing activities | 327,923 | (2,983,615) |
| EFFECT OF EXCHANGE RATE ON CASH | (1,695,331) | (3,211,290) |
| (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (1,970,324) | (5,220,584) |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period | 31,570,644 | 34,672,644 |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of period | 29,600,320 | 29,452,060 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
| Cash paid for interest | 307 | 60,365 |
| Cash paid for income taxes | $ 77,806 | $ 64,844 |
